Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels*
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate whether administration of afelimomab, an anti-tumor necrosis factor F(ab')2 monoclonal antibody fragment, would reduce 28-day all-cause mortality in patients with severe sepsis and elevated serum levels of IL-6. DESIGN: Prospective, randomized, double-blind, placebo-controlled, multiple-center, phase III clinical trial. SETTING: One hundred fifty-seven intensive care units in the United States and Canada. PATIENTS: Subjects were 2,634 patients with severe sepsis secondary to documented infection, of whom 998 had elevated interleukin-6 levels. INTERVENTIONS: Patients were stratified into two groups by means of a rapid qualitative interleukin-6 test kit designed to identify patients with serum interleukin-6 levels above (test positive) or below (test negative) approximately 1000 pg/mL. Of the 2,634 patients, 998 were stratified into the test-positive group, 1,636 into the test-negative group. They were then randomly assigned 1:1 to receive afelimomab 1 mg/kg or placebo for 3 days and were followed for 28 days. The a priori population for efficacy analysis was the group of patients with elevated baseline interleukin-6 levels as defined by a positive rapid interleukin-6 test result. MEASUREMENTS AND MAIN RESULTS: In the group of patients with elevated interleukin-6 levels, the mortality rate was 243 of 510 (47.6%) in the placebo group and 213 of 488 (43.6%) in the afelimomab group. Using a logistic regression analysis, treatment with afelimomab was associated with an adjusted reduction in the risk of death of 5.8% (p = .041) and a corresponding reduction of relative risk of death of 11.9%. Mortality rates for the placebo and afelimomab groups in the interleukin-6 test negative population were 234 of 819 (28.6%) and 208 of 817 (25.5%), respectively. In the overall population of interleukin-6 test positive and negative patients, the placebo and afelimomab mortality rates were 477 of 1,329 (35.9%)and 421 of 1,305 (32.2%), respectively. Afelimomab resulted in a significant reduction in tumor necrosis factor and interleukin-6 levels and a more rapid improvement in organ failure scores compared with placebo. The safety profile of afelimomab was similar to that of placebo. CONCLUSIONS: Afelimomab is safe, biologically active, and well tolerated in patients with severe sepsis, reduces 28-day all-cause mortality, and attenuates the severity of organ dysfunction in patients with elevated interleukin-6 levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674 · cited 2×
“Organ dysfunction was assessed at baseline and during the study using the Multiple Organ Dysfunction (MOD) and Sequential Organ Failure Assessment (SOFA) scores (39, 40).”
MethodAngus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., & Pinsky, M. R. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107000-00002 · Cited by 8,503
Le Gall, J.-R. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.270.24.2957 · Cited by 7,773
Shock and Tissue Injury Induced by Recombinant Human Cachectin
Tracey, K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey, T. J., Zentella, A., Albert, J. D., et al. (1986) · Science · doi:10.1126/science.3764421 · Cited by 2,549
Multiple Organ Dysfunction Score: A reliable descriptor of a complex clinical outcome
Marshall, J. C., Cook, D. J., Christou, N. V., Bernard, G. R., Sprung, C. L., & Sibbald, W. J. (1995) · Critical Care Medicine · doi:10.1097/00003246-199510000-00007 · Cited by 2,532
Self-citationDetection of circulating tumor necrosis factor after endotoxin administration
Michie, H. R., Manogue, K. R., Spriggs, D. R., Revhaug, A., O'Dwyer, S., Dinarello, C. A., Cerami, A., Wolff, S. M., & Wilmore, D. W. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806093182301 · Cited by 1,677
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
Fisher, C. J., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C., Abraham, E., Schein, R. M. H., & Benjamin, E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342603 · Cited by 1,241
Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome
Casey, L. C., Balk, R. A., & Bone, R. C. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-8-199310150-00001 · Cited by 1,041
Treating Patients with Severe Sepsis
Wheeler, A. P., & Bernard, G. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400307 · Cited by 992
The Role of Interleukin-1 in Disease
Epstein, F. H., Dinarello, C. A., & Wolff, S. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280207 · Cited by 954
Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever
Cannon, J. G., Tompkins, R. G., Gelfand, J. A., Michie, H. R., Stanford, G. G., van der Meer, J. W. M., Endres, S., Lonnemann, G., Corsetti, J., Chernow, B., et al. (1990) · Journal of Infectious Diseases · doi:10.1093/infdis/161.1.79 · Cited by 751
Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group.
Bone, R. C., Fisher, C. J., Clemmer, T. P., Gj, S., METZ, C. A., & BALK, R. A. (1989) · PubMed · Cited by 689
Abraham, E. (1998) · The Lancet · doi:10.1016/s0140-6736(00)80009-4 · Cited by 624
Abraham, E. H., Anzueto, A., Gutiérrez, G., Tessler, S., Pedro, G. S. S., Wunderink, R. G., Nogare, A. R. D., Nasraway, S. A., Berman, S., Cooney, R. N., et al. (1998) · PubMed · Cited by 622
Natanson, C., Eichenholz, P. W., Danner, R. L., Eichacker, P. Q., Hoffman, W. D., Kuo, G. C., Banks, S. M., MacVittie, T. J., & Parrillo, J. E. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.3.823 · Cited by 568
Sepsis syndrome: A valid clinical entity
BONE, R. C., FISHER, C. J., CLEMMER, T. P., SLOTMAN, G. J., METZ, C. A., & BALK, R. A. (1989) · Critical Care Medicine · doi:10.1097/00003246-198905000-00002 · Cited by 537
Cohen, J., & Carlet, J. (1996) · Critical Care Medicine · doi:10.1097/00003246-199609000-00002 · Cited by 501
Suffredini, A. F., Harpel, P. C., & Parrillo, J. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198905043201802 · Cited by 476
Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome
Marshall, J. C. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107001-00032 · Cited by 457
Self-citationFISHER, C. J., OPAL, S. M., DHAINAUT, J.-F., STEPHENS, S., ZIMMERMAN, J. L., NIGHTINGALE, P., HARRIS, S. J., SCHEIN, R. M. H., PANACEK, E. A., VINCENT, J.-L., et al. (1993) · Critical Care Medicine · doi:10.1097/00003246-199303000-00006 · Cited by 427
Self-citationReinhart, K., Wiegand-Lohnert, C., Grimminger, F., Kaul, M., Withington, S., Treacher, D., Eckart, J., Willatts, S., Bouza, C., Krausch, D., et al. (1996) · Critical Care Medicine · doi:10.1097/00003246-199605000-00003 · Cited by 361
Self-citationDesigns for group sequential tests
Fleming, T. R., Harrington, D. P., & O'Brien, P. C. (1984) · Controlled Clinical Trials · doi:10.1016/s0197-2456(84)80014-8 · Cited by 353
Plasma tumor necrosis factor and mortality in critically ill septic patients
DEBETS, J. M. H., KAMPMEIJER, R., P, M., BUURMAN, W. A., & VAN DER LINDEN, C. J. (1989) · Critical Care Medicine · doi:10.1097/00003246-198906000-00001 · Cited by 321
Derangements of Coagulation and Fibrinolysis in Critically III Patients with Sepsis and Septic Shock
Vervloet, M., Thijs, L., & Hack, C. (1998) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2007-995821 · Cited by 299
Hack, C. E., Aarden, L. A., & Thus, L. G. (1997) · Advances in Immunology · doi:10.1016/s0065-2776(08)60597-0 · Cited by 280
Fast, D. J., Schlievert, P. M., & Nelson, R. D. (1989) · Infection and Immunity · doi:10.1128/iai.57.1.291-294.1989 · Cited by 272
Why immunomodulatory therapies have not worked in sepsis
Abraham, E. (1999) · Intensive Care Medicine · doi:10.1007/s001340050903 · Cited by 252
Hinshaw, L. B., Tekamp-Olson, P., Chang, A. C. K., Lee, P. A., Taylor, F. B., Murray, C. K., Peer, G., Emerson, T. E., Passey, R. B., & Kuo, G. C. (1990) · PubMed · Cited by 239
Time course of cytokine levels in sepsis
Thijs, L. G., & Hack, C. E. (1995) · Intensive Care Medicine · doi:10.1007/bf01740764 · Cited by 202
Gall, J. R. L. (1995) · JAMA · doi:10.1001/jama.273.8.644 · Cited by 177
Should morbidity replace mortality as an endpoint for clinical trials in intensive care?
Petros, A., Marshall, J. C., & van Saene, H. K. F. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90347-x · Cited by 114
Self-citationClinical trials of mediator-directed therapy in sepsis: what have we learned?
Marshall, J. C. (2000) · Intensive Care Medicine · doi:10.1007/s001340051122 · Cited by 113
Self-citationFiedler, V. B., Loof, I., Sander, E., Voehringer, V., Galanos, C., & Fournel, M. A. (1992) · PubMed · Cited by 113
Groote, M. A. D. (1989) · JAMA · doi:10.1001/jama.262.2.249 · Cited by 102
Plasma Tumor Necrosis Factor Levels in Patients With Presumed Sepsis
Groote, M. A. D. (1989) · JAMA · doi:10.1001/jama.1989.03430020091035 · Cited by 76
The Use of Interim Analysis for Sample Size Adjustment
Herson, J., & Wittes, J. T. (1993) · Drug Information Journal · doi:10.1177/009286159302700317 · Cited by 65
Monoclonal antibodies to human tumor necrosis factor α: In vitro and in vivo application
Möller, A., Emling, F., Blohm, D. H., Schlick, E., & Schollmeier, K. (1990) · Cytokine · doi:10.1016/1043-4666(90)90011-h · Cited by 59
Gallagher, J. J., Fisher, C. J., Sherman, B. W., Munger, M. A., Meyers, B., Ellison, T., Fischkoff, S. A., Barchuk, W., Teoh, L. S., & Velagapudi, R. B. (2001) · Intensive Care Medicine · doi:10.1007/s001340100973 · Cited by 58
Self-citationANTI-TUMOR NECROSIS FACTOR ANTIBODY TREATMENT OF RECURRENT BACTEREMIA IN A BABOON MODEL
Schlag, G., Redl, H. R., Davies, J., & Haller, I. (1994) · Shock · doi:10.1097/00024382-199407000-00002 · Cited by 37
ALLEN, G. W. (1883) · New England Journal of Medicine · doi:10.1056/nejm188308091090606 · Cited by 36
Interim analyses and early termination of clinical trials
Choi (1997) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543409708835205 · Cited by 7
Cited by
Pierrakos, C., & Vincent, J.-L. (2010) · Critical Care · doi:10.1186/cc8872 · Cited by 1,377
Sepsis: pathophysiology and clinical management
Gotts, J. E., & Matthay, M. A. (2016) · BMJ · doi:10.1136/bmj.i1585 · Cited by 1,243
van der Poll, T., Shankar-Hari, M., & Wiersinga, W. J. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.012 · Cited by 1,010
Advances in the understanding and treatment of sepsis-induced immunosuppression
Venet, F., & Monneret, G. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.165 · Cited by 981
Animal Models of sepsis: setting the stage
Buras, J. A., Holzmann, B., & Sitkovsky, M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1854 · Cited by 843
Metadata
- Authors
- Panacek, E. A., Marshall, J. C., Albertson, T. E., Johnson, D. H., Johnson, S., MacArthur, R. D., Miller, M., Barchuk, W. T., Fischkoff, S., Kaul, M., Teoh, L., Van Meter, L., Daum, L., Lemeshow, S., Hicklin, G., & Doig, C.
- Venue
- Critical Care Medicine
- Published
- 2004-11
- Volume
- 32
- Issue
- 11
- Pages
- 2173-2182
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2104010066
- Cited by
- 387
- References
- 45
- FWCI
- 15.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.